News|Articles|January 5, 2024
NeurologyLive® Friday 5 — January 5, 2024
Author(s)NeurologyLive® Staff
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 5, 2024.
Advertisement
Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
1: 5 Clinical Trial Readouts in Neurology to Look for in 2024
Take a look at 5 of the most-anticipated clinical trial data readouts expected in 2023 that neurology health care professionals should keep their eyes on.
2: Preclinical Neuroinflammation Modulation and Neuroprotection With Fosgonimeton in AD: Kevin Church, PhD
The chief scientific officer at Athira Pharma talked about preclinical results presented at the 2023 Society for Neuroscience Annual Meeting on fosgonimeton, a potential treatment for Alzheimer disease and other neurodegenerative diseases. [WATCH TIME: 6 minutes]
3: FDA Action Update, December 2023: Approval and Clearances
Catch up on any of the neurology news headlines you may have missed over the course of December 2023, compiled all into one place by the NeurologyLive® team.
4: NeuroVoices: Jennifer Gudeman, PharmD, on the Effect of Once-Nightly Sodium Oxybate in Narcolepsy Subtypes
The senior vice president of medical and clinical affairs for Avadel Pharmaceuticals provided perspective on a recently published analysis demonstrating the benefits of once-nightly sodium oxybate in narcolepsy type 1 and type 2.
5: A Dive Into the Neurological Impact of Long COVID and Hyperbaric Oxygen Therapy: Amir Hadanny, MD, PhD
The chief medical research officer and head of research at Aviv Clinics discussed the impact of long COVID on patients and shared findings from a recently published study on using hyperbaric oxygen therapy protocol as a treatment for these patients. [WATCH TIME: 8 minutes]
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Related Articles
- NeurologyLive® Friday 5 — September 12, 2025
September 12th 2025
- Expanding the Alzheimer Drug Development Pipeline
September 12th 2025
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive
1
Expanding the Alzheimer Drug Development Pipeline
2
FDA Hands Complete Response Letter to SL1009 for Pyruvate Dehydrogenase Complex Deficiency
3
DORAs Carry Lower Real-World Abuse, New Phase 3 Argus Data, RAP-219 Meets Primary End Point
4
NeurologyLive® Friday 5 — September 12, 2025
5